Seelos Therapeutics, Inc. (Nasdaq: SEEL) Soars on update for its SLS-002 (intranasal racemic ketamine) for PTSD
C2000-2021 InvestorIdeas.com tm
Read more: https://www.investorideas.com/news/2024/biotech/09241Seelos-Therapeutics-SEEL.asp
Text source: Investorideas.com newswire, breaking stock market